USP9X upregulates the expression of ABCB1 and MRP2 by stabilizing β-catenin, thus affecting cisplatin resistance in nasopharyngeal carcinoma (NPC) cells [62]. This evidence concerns the gene USP9X and nasopharyngeal carcinoma.